https://www.selleckchem.com/pr....oducts/napabucasin.h
th C-CRT independent of the universally recognized T- and N-stages. Under the name of uncommon bladder cancers are gathered rare histological entities which represent less than 5% of bladder tumors. There is not a clear and consensual therapeutic management for these entities. To review a single-institution 10-year experience with rare form of bladder cancers detailing the diagnosis, treatment, and patient outcome. We performed a retrospective review of 27 medical records of rare bladder cancer form treated at our center between Feb
Like
Comment
Share
